K-Strophanthoside

Suppliers

Names

[ Name ]:
K-Strophanthoside

[Synonym ]:
STROPHANTHOSIDE,K
k-strophantoside
Strophanthosid-K
STROPHANTHOSIDE,K-(RG)
k-strofantozyd
ihydroxy-19-oxo
k-strophantosid
K-strophanthin variable mixture

Chemical & Physical Properties

[ Density]:
1.49g/cm3

[ Boiling Point ]:
1027.2ºC at 760mmHg

[ Melting Point ]:
200ºC

[ Molecular Formula ]:
C₄₂H₆₄O₁₉

[ Molecular Weight ]:
872.94600

[ Flash Point ]:
304ºC

[ Exact Mass ]:
872.40400

[ PSA ]:
290.05000

[ Index of Refraction ]:
1.631

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :: FH5091000

CHEMICAL NAME :: 5-beta-Card-20(22)-enolide, 3-beta-((O-beta-D-glucopyranosyl-(1-6)-O-beta-D-gluco pyranosyl- (1-4)-2,6-dideoxy-3-O-methyl-beta-D-ribo-hexopyranosy l)oxy)-5,14-dihydroxy -19-oxo-

CAS REGISTRY NUMBER :: 33279-57-1

LAST UPDATED :: 199012

DATA ITEMS CITED :: 8

MOLECULAR FORMULA :: C42-H64-O19

MOLECULAR WEIGHT :: 873.06

WISWESSER LINE NOTATION :: L E5 B666TJ AVH E1 IQ F- DT5OVTJ& OO- FT6OTJ B1 DO1 CO- BT6OTJ CQ DQ F1Q EO- BT6OTJ CQ DQ EQ

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 8161 ug/kg

TOXIC EFFECTS :: Behavioral - convulsions or effect on seizure threshold

REFERENCE :: ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 11,908,1961

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intracerebral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 34 ug/kg

TOXIC EFFECTS :: Behavioral - convulsions or effect on seizure threshold

REFERENCE :: ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 11,908,1961

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Mammal - cat

DOSE/DURATION :: 5 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: FARMA8 Farmacognosia. (Madrid, Spain) V.1-27, 1942-62. Discontinued. Volume(issue)/page/year: 13,375,1953

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Parenteral

SPECIES OBSERVED :: Mammal - cat

DOSE/DURATION :: 1900 ug/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: APPHAX Acta Poloniae Pharmaceutica. For English translation, see APPFAR. (Ars Polona, POB 1001, 00-680 Warsaw 1, Poland) V.1- 1937- Volume(issue)/page/year: 34,431,1977

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Mammal - cat

DOSE/DURATION :: 130 ug/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: 85ELDJ "Die Herzwirksamen Glykoside," Baumgarten, G., and W. Forster, Leipzig, Ger. Dem. Rep., VEB Georg Thieme, 1963 Volume(issue)/page/year: -,194,1963

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Unreported

SPECIES OBSERVED :: Mammal - cat

DOSE/DURATION :: 187 ug/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: 85ELDJ "Die Herzwirksamen Glykoside," Baumgarten, G., and W. Forster, Leipzig, Ger. Dem. Rep., VEB Georg Thieme, 1963 Volume(issue)/page/year: -,124,1963

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Mammal - species unspecified

DOSE/DURATION :: 550 ug/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: APJUA8 Acta Pharmaceutica Jugoslavica. (FDH, Masarykova 2, 41000 Zagreb, Yugoslavia) V.1-41, 1951-1991. Volume(issue)/page/year: 24,179,1974

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Mammal - species unspecified

DOSE/DURATION :: 240 ug/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: APJUA8 Acta Pharmaceutica Jugoslavica. (FDH, Masarykova 2, 41000 Zagreb, Yugoslavia) V.1-41, 1951-1991. Volume(issue)/page/year: 24,179,1974

Related Compounds

k-33
K-13 (ACE inhib)
K-7174 (dihydrochloride)
K-80003
K-Ras(G12C) inhibitor 9
K[η5-C9H7(CO)3Mo]
Cuprate(4-), (2-(amino-kappaN)ethanol-kappaO)ammine(mu-(7-(benzoylamino)-3-((3,3'-di(hydroxy-kappaO)-4'-((1-(hydroxy-kappaO)-4,8-disulfo-2-naphthalenyl)azo-kappaN1)(1,1'-biphenyl)-4-yl)azo-kappaN1)-4-(hydroxy-kappaO)-1,5-naphthalenedisulfonato(8-)))di-, tetrasodium
Cuprate(3-), [mu-[5-[2-[4-[2-[6-[4-[2-[2-(carboxy-kappaO)phenyl]diazenyl-kappaN1]-4,5-dihydro-3-methyl-5-(oxo-kappaO)-1H-pyrazol-1-yl]-2-(hydroxy-kappaO)-4-sulfo-1-naphthalenyl]diazenyl-kappaN1]-3-(hydroxy-kappaO)-7-sulfo-1-naphthalenyl]diazenyl]-2-hydroxybenzoato(7-)]]di-, sodium (1:3)
Cuprate(3-), (mu-(7-((4'-((8-(acetylamino)-1-(hydroxy-kappaO)-3-sulfo-2-naphthalenyl)azo-kappaN1)-3,3'-di(hydroxy-kappaO)(1,1'-biphenyl)-4-yl)azo-kappaN1)-8-(hydroxy-kappaO)-1,6-naphthalenedisulfonato(7-)))di-, trisodium
Cuprate(3-), [2-[2-[[2-[2-(hydroxy-kappaO)-3-sulfo-5-[[2-(sulfooxy)ethyl]sulfonyl]phenyl]diazenyl-kappaN2]phenylmethyl]diazenyl-kappaN1]-5-sulfobenzoato(6-)-kappaO]-, hydrogen (1:3)
Cuprate(4-), [mu-[5-(acetylamino)-3-[2-[3,3'-di(hydroxy-kappaO)-4'-[2-[1-(hydroxy-kappaO)-3,6-disulfo-2-naphthalenyl]diazenyl-kappaN1][1,1'-biphenyl]-4-yl]diazenyl-kappaN1]-4-(hydroxy-kappaO)-2,7-naphthalenedisulfonato(8-)]]-, sodium (1:4)
Cuprate(4-), (mu-(4-amino-6-((3,3'-di(hydroxy-kappaO)-4'-((2-(hydroxy-kappaO)-3,6-disulfo-1-naphthalenyl)azo-kappaN1)(1,1'-biphenyl)-4-yl)azo-kappaN1)-5-(hydroxy-kappaO)-1,3-naphthalenedisulfonato(8-)))di-, tetrasodium
Cuprate(4-), [mu-[[7,7'-[[6-(phenylamino)-1,3,5-triazine-2,4-diyl]diimino]bis[4-(hydroxy-kappaO)-3-[[2-(hydroxy-kappaO)-5-sulfophenyl]azo-kappaN1]-2-naphthalenesulfonato]](8-)]]di-, tetrasodium
Cuprate(4-), [mu-[[6,6'-[[3,3'-di(hydroxy-kappaO)[1,1'-biphenyl]-4,4'-diyl]bis[(2,1-diazenediyl-kappaN1)[4,5-dihydro-3-methyl-5-(oxo-kappaO)-1H-pyrazole-4,1-diyl]]]bis[1,3-naphthalenedisulfonato]](8-)]]di-, hydrogen (1:4)
Cuprate(4-), [mu-[[3,3'-[[3,3'-di(hydroxy-kappaO)[1,1'-biphenyl]-4,4'-diyl]bis(2,1-diazenediyl-kappaN1)]bis[5-amino-4-(hydroxy-kappaO)-2,7-naphthalenedisulfonato]](8-)]]tetrakis[2,2'-(imino-kappaN)bis[ethanol]]di-, hydrogen (1:4)
Cuprate(4-), [mu-[[3,3'-[[3,3'-di(hydroxy-kappaO)[1,1'-biphenyl]-4,4'-diyl]bis(2,1-diazenediyl-kappaN1)]bis[5-amino-4-(hydroxy-kappaO)-2,7-naphthalenedisulfonato]](8-)]]bis[2,2'-(imino-kappaN)bis[ethanol-kappaO]]di-, lithium sodium (1:3:1)

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.